Taysha Gene Therapies, Inc. (TSHA)
5.79
+0.03
(+0.52%)
USD |
NASDAQ |
Dec 12, 16:00
5.795
0.00 (0.00%)
After-Hours: 20:00
Taysha Gene Therapies Debt to Equity Ratio: 0.3174 for Sept. 30, 2025
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| AngioDynamics, Inc. | 0.0537 |
| Anavex Life Sciences Corp. | 0.00 |
| Bolt Biotherapeutics, Inc. | 0.7348 |
| Neurogene, Inc. | 0.0384 |
| Aspire Biopharma Holdings, Inc. | -0.7521 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 316.55M |
| Total Liabilities (Quarterly) | 97.56M |
| Shareholders Equity (Quarterly) | 218.99M |
| Current Ratio | 10.47 |
| Net Debt Paydown Yield | -0.26% |